Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting - Seite 2

Across all dose levels as of the cutoff date, median event free survival (EFS) and overall survival (OS) were 8 months and not reached, respectively. A more in-depth analysis of the data and updated EFS/OS data using a later cut-off date will be presented during Dr. Nieto’s oral presentation.

The second presentation will be a poster featuring the design of Affimed’s phase 2 LuminICE-203 clinical trial investigating AFM13 in combination with Artiva’s AlloNK (also known as AB-101), an allogeneic, non-genetically modified NK cell therapy candidate. The open-label, multi-center, multi-cohort study (NCT05883449) study is based on the unprecedented results achieved in the investigational AFM13-104 study and will evaluate the efficacy and safety of the combination in patients with r/r HL and certain r/r CD30+ PTCL subtypes. Affimed has recently received Fast-track designation for the AFM13/AB-101 combination.

“AFM13 in combination with allogeneic NK cells has shown impressive activity with a good tolerability and safety profile demonstrating the potential of this therapy for relapsed/refractory CD30-positive lymphoma patients that have exhausted all options,” said Dr. Andreas Harstrick, Chief Medical Officer at Affimed. “We are confident that the phase 2 LuminICE-203 study will allow us to build on the outstanding results we have seen in the AFM13-104 trial and look forward to providing updates as the study progresses.”

Details of AFM13 Oral Presentation and Abstract

Title: Innate Cell Engager (ICE) AFM13 Combined with Preactivated and Expanded (P+E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas: Final Results
Session: Cellular Immunotherapies: Early Phase and Investigational Therapies: Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas
Date & Time: Monday, December 11, 2023 at 11:45 a.m. PST
Location: San Diego Convention Center, Room 6CF

Details of LuminICE-203 Poster Presentation

Title: AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Relapsed or Refractory Hodgkin Lymphoma and CD30⁺ Peripheral T-Cell Lymphoma: A Phase 2 Study (LuminICE)
Session: Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster III
Session Date & Time: Monday, December 11, 2023 from 6:00 p.m. - 8:00 p.m. PST
Location: San Diego Convention Center, Halls G-H

The full abstracts for both presentations are available on the ASH conference website via the following link: 65th ASH Annual Meeting & Exposition - Hematology.org